OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014

OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 
on March 11, 2014 
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 25, 2014 /CNW/ - 
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the 
Company's fourth quarter and year-ended 2013 financial results will be 
released on Tuesday, March 11, 2014, and that the Company will host a 
conference call and live webcast at 4:30 p.m. ET that afternoon. Management 
will provide an overview of the company's financial results, development 
programs and a general business update. 
To access the webcast, log on to the Investor Relations page of the OncoGenex 
website at www.oncogenex.com. Alternatively, you may access the live 
conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 
(International). A webcast replay will be available approximately two hours 
after the call and will be archived on www.oncogenex.com for 90 days. 
ABOUT ONCOGENEX OncoGenex is a biopharmaceutical company committed to the 
development and commercialization of new therapies that address treatment 
resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with 
each product candidate having a distinct mechanism of action and representing 
a unique opportunity for cancer drug development. OncoGenex and Teva 
Pharmaceutical Industries Ltd. have entered a global collaboration and license 
agreement to develop and commercialize OncoGenex' lead drug candidate, 
custirsen. Custirsen is currently in Phase 3 clinical development as a 
treatment in men with metastatic castrate-resistant prostate cancer and in 
patients with advanced, unresectable non-small cell lung cancer. Apatorsen is 
currently being evaluated in seven randomized Phase 2 trials for a variety of 
cancers and OGX-225 is currently in pre-clinical development. More information 
is available at www.OncoGenex.com and at the company's Twitter account: 
https://twitter.com/OncoGenex_IR.
 

SOURCE  OncoGenex Pharmaceuticals, Inc. 
Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403, Investor 
Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535 
http://www.OncoGenex.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2014/25/c7025.html 
CO: OncoGenex Pharmaceuticals, Inc.
ST: British Columbia
NI: HEA MTC CONF  
-0- Feb/25/2014 11:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.